Drug Approval | October 14, 2024
Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3
Indoco is comprehensively working on the remedial action plan
Indoco is comprehensively working on the remedial action plan
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Subscribe To Our Newsletter & Stay Updated
